Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22175776 | 0.85 | ACE (0.36) | MAPTACE | |
| SCHEMBL11191253 | 0.83 | SLC5A1 (0.34) | MAPTSLC5A1P2RX7 | |
| SCHEMBL14827920 | 0.79 | SLC5A1 (0.32) | SLC5A1 | |
| SCHEMBL24676931 | 0.74 | — | — | |
| SCHEMBL288354 | 0.74 | P2RX7 (0.45) | SLC5A1ACETSHRP2RX7 | |
| SCHEMBL7265419 | 0.74 | P2RX7 (0.45) | SLC5A1ACETSHRP2RX7 | |
| SCHEMBL14750046 | 0.74 | P2RX7 (0.45) | SLC5A1ACETSHRP2RX7 | |
| SCHEMBL23773702 | 0.71 | L3MBTL1 (0.31) | — | |
| SCHEMBL14749790 | 0.71 | L3MBTL1 (0.31) | — | |
| SCHEMBL14749808 | 0.69 | PIK3C3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206196-A1 | Antiviral Drugs | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206196-A1 | Antiviral Drugs | ACE2, MAVS, EIF2AK2 | MAPT 3318/4885SLC5A1 696/4885ACE 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.